Quarterly UpdatesJun 16, 2026, 08:12 AM
Sanuwave Lowers Q2 2026 Revenue Guidance to $8.5M-$9.5M
AI Summary
Sanuwave Health, Inc. updated its revenue guidance for the second quarter of 2026 to a range of $8.5 million to $9.5 million, which is below previous expectations. This revision is attributed to significant market disruption impacting Ultramist system sales, including widespread CMS reimbursement clawbacks and the availability of used systems from closing wound care practices. Despite these challenges, the company anticipates record unit sales for applicators in Q2.
Key Highlights
- Sanuwave updated Q2 2026 revenue guidance to $8.5 million - $9.5 million.
- The revised guidance is below the previous guidance provided on May 13.
- Market disruption is significantly impacting Ultramist system capital equipment sales.
- Widespread CMS reimbursement clawbacks are causing wound care practices to close.
- Availability of used Ultramist systems is cannibalizing new system sales.
- The company is on pace for record quarterly unit volume of applicator shipments in Q2.
- CEO Morgan Frank noted a reversal of market improvement trends in May and June.
Price Impact
More from SNWV